Amneal Pharmaceuticals Inc. Class A Common Stock (AMRX) Stock Forecast
Alert
Its only available to paid users.
USD 7.08
(+32.15%)
Based on the Amneal Pharmaceuticals Inc. Class A Common Stock stock forecast from 3 analysts, the average analyst target price for Amneal Pharmaceuticals Inc. Class A Common Stock is USD 7.08 over the next 12 months. Amneal Pharmaceuticals Inc. Class A Common Stock’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Amneal Pharmaceuticals Inc. Class A Common Stock is Slightly Bearish, which is based on 4 positive signals and 6 negative signals. At the last closing, Amneal Pharmaceuticals Inc. Class A Common Stock’s stock price was USD 5.36. Amneal Pharmaceuticals Inc. Class A Common Stock’s stock price has changed by -5.80% over the past week, -9.31% over the past month and +226.83% over the last year.
No recent analyst target price found for Amneal Pharmaceuticals Inc. Class A Common Stock
No recent average analyst rating found for Amneal Pharmaceuticals Inc. Class A Common Stock
Company Overview Amneal Pharmaceuticals Inc. Class A Common Stock
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey. Address: 400 Crossing Boulevard, Bridgewater, NJ, United States, 08807 Read Less
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE...Read More
Frequently Asked Questions About Amneal Pharmaceuticals Inc. Class A Common Stock (AMRX) Stock
Based on ratings from 3 analysts Amneal Pharmaceuticals Inc. Class A Common Stock's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 3 buy, sell and hold ratings.
Unfortunately we do not have enough data on AMRX's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for AMRX is USD 7.08 over the next 12 months. The maximum analyst target price is USD 8 while the minimum anlayst target price is USD 6.25.
AMRX stock's Price/Earning ratio is 89.83.
Our analysis grades AMRX stock's Price / Earning ratio at F. This means that AMRX stock's Price/Earning ratio is above 73% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NYE exchange.
Based on this AMRX may be a overvalued for its sector.
The last closing price of AMRX's stock was USD 5.36.
The most recent market capitalization for AMRX is USD 1.68B.
Based on targets from 3 analysts, the average taret price for AMRX is projected at USD 7.08 over the next 12 months.
This means that AMRX's stock price may go up by +32.15% over the next 12 months.
Following are ETFs with the highest allocation to Amneal Pharmaceuticals Inc. Class A Common Stock's stock :
As per our most recent records Amneal Pharmaceuticals Inc. Class A Common Stock has 7,850 Employees.
Amneal Pharmaceuticals Inc. Class A Common Stock's registered address is 400 Crossing Boulevard, Bridgewater, NJ, United States, 08807.
You can get more information about it from Amneal Pharmaceuticals Inc. Class A Common Stock's website at https://www.amneal.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AMRX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
